Ligand Pharmaceuticals Inc. (LGND)
Ligand Pharmaceuticals Q1 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company's royalty-focused business model and diversified portfolio as key drivers of continued earnings growth. Ligand provides capital and technology to drug and medical device developers in exchange for royalties, creating a portfolio of more than 100 commercial and development-stage assets that generate high-margin returns.
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Financial Officer Conference Call Participants Trevor Allred - Oppenheimer & Co. Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Lauren Hay - Corporate Participant Melanie Herman - Corporate Participant Octavio Espinoza - Chief Financial Officer Paul J. Hadden - Senior Vice President of Investments & Business Development Todd C.
Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. LGND's business model supports sustainable revenue through royalties and partnerships with leading pharma firms.
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chief Executive Officer Rich Baxter – Senior Vice President-Investment Operations Tavo Espinoza – Chief Financial Officer Lauren Hay – Vice President-Strategic Planning and Investment Analytics Conference Call Participants Doug Miehm – RBC Capital Markets Matt Hewitt – Craig-Hallum Trevor Allred – Oppenheimer Annabel Samimy – Stifel John Vandermosten – Zacks Operator Thank you for standing by. My name is Kate and I will be your conference operator today.
Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investment Analytics Conference Call Participants Matt Hewitt - Craig-Hallum Joseph Pantginis - HC Wainwright Douglas Miehm - RBC Capital Markets Trevor Allred - Oppenheimer Larry Solow - CJS Securities John Vandermosten - Zack Melanie Herman Good morning everyone and welcome to Ligand's Fourth Quarter and Full Year 2024 Earnings Call. During the call today, we will review the financial results we released earlier today and provide commentary on our partner pipeline and business development activity, followed by a question and answer session.
Looking Back On Ligand Pharmaceuticals
Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of 20% annually in the years ahead. Analysts are universally optimistic, with multiple Buy ratings and price targets ranging from $135 to $160 a share.
